SABS vs IMVT vs ARGX vs HALO vs ADMA

For growth investors, argenx SE (ARGX) is the stronger pick with 90.

1% revenue growth year-over-year, versus -100. 0% for SAB Biotherapeutics, Inc. (SABS). ADMA Biologics, Inc. (ADMA) offers the better valuation at 14. 1x trailing P/E (8. 9x forward), making it the more compelling value choice. Analysts rate SAB Biotherapeutics, Inc. (SABS) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, ADMA Biologics, Inc.

(ADMA) is the cheapest at 14. 1x versus argenx SE at 40. 1x. On forward P/E, Halozyme Therapeutics, Inc. is actually cheaper at 8. 1x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, ADMA Biologics, Inc.

(ADMA) delivered a total return of +386. 8%, compared to -95. 9% for SAB Biotherapeutics, Inc. (SABS). Over 10 years, the gap is even starker: ARGX returned +33. 2% versus SABS's -96. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), argenx SE (ARGX) is the lower-risk stock at 0.

52β versus Immunovant, Inc. 's 1. 37β — meaning IMVT is approximately 162% more volatile than ARGX relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 17% for ADMA Biologics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), argenx SE (ARGX) is pulling ahead at 90.

1% versus -100. 0% for SAB Biotherapeutics, Inc. (SABS). On earnings-per-share growth, the picture is similar: SAB Biotherapeutics, Inc. grew EPS 78. 5% year-over-year, compared to -45. 2% for Immunovant, Inc.. Over a 3-year CAGR, ARGX leads at 116. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

argenx SE (ARGX) is the more profitable company, earning 31.

1% net margin versus 0. 0% for Immunovant, Inc. — meaning it keeps 31. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HALO leads at 58. 4% versus 0. 0% for IMVT. At the gross margin level — before operating expenses — ARGX leads at 89. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Halozyme Therapeutics, Inc.

(HALO) trades at 8. 1x forward P/E versus 30. 0x for argenx SE — 21. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ADMA: 165. 6% to $22. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Halozyme Therapeutics, Inc.

(HALO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 56), +570. 7% 10Y return). Both have compounded well over 10 years (HALO: +570. 7%, IMVT: +173. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SABS is a small-cap quality compounder stock; IMVT is a small-cap quality compounder stock; ARGX is a mid-cap high-growth stock; HALO is a small-cap high-growth stock; ADMA is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.